Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

Rhea-AI Summary

Seer (Nasdaq: SEER) will present at the American Society of Human Genetics (ASHG) Annual Meeting, October 14-18, 2025 in Boston, highlighting how proteomics complements genomics to advance precision medicine.

Seer will host a featured CoLab session on October 16, 2025, 2:30-3:00 p.m. ET showcasing Proteograph-enabled multi-omic studies, including xenotransplantation immune profiling and isoform-specific biomarkers in idiopathic pulmonary fibrosis. Multiple independent research groups will also present Proteograph-generated findings on October 16 across poster and session formats, illustrating adoption of Seer’s Proteograph Product Suite for proteogenomic discovery and biomarker identification.

Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers

REDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics (ASHG) 2025 Annual Meeting, taking place October 14-18 in Boston. As human genetics research increasingly moves from sequence to function, Seer’s presence at ASHG reflects how proteomics is becoming an essential complement to genomics in understanding disease biology and accelerating precision medicine. Seer will host a featured CoLab session and will be represented in multiple scientific presentations demonstrating how the Proteograph^® Product Suite enables researchers to translate genomic data into biological and clinical insight.

Seer CoLab Session

Advancing Precision Medicine Through Multi-Omics: Clinical Insights from Xenotransplantation and Fibrosis
Date/Time: October 16, 2025 | 2:30-3:00 p.m. ET
Location: Theater 1, Exhibit Hall

This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research.

• Brendan Keating, PhD, Associate Professor, NYU Langone Health, will present findings from gene-edited pig organ xenotransplants into humans, where integrated omics revealed immune and physiological dynamics critical for advancing compassionate use and first-in-human trials.
  
• Gloria Sheynkman, PhD, Assistant Professor, University of Virginia School of Medicine, will discuss how proteomic profiling identified isoform-specific biomarkers predicting survival differences in idiopathic pulmonary fibrosis, pointing to new avenues for targeted therapy in complex disease.

Together, these talks show how proteomics and genomics converge to uncover novel biomarkers, deepen understanding of disease mechanisms, and advance clinical translation.

Scientific Presentations Featuring Seer Technology

In addition to the CoLab session, several independent research groups will present findings generated using Seer’s Proteograph platform, reflecting its growing adoption across global academic and clinical institutions. These studies explore how Seer’s proteomic data can clarify and enhance prior findings from affinity-based methods and integrate with genomic datasets for disease discovery.

• Triangulating orthogonal proteomic profiling methods to yield high-confidence protein targets
  Presenter: Joshua Bis
  Date/Time: October 16, 2025 | 12:00-1:00 p.m. | Poster 4063T
  
• Proteogenomic prioritization of human knock-out mutations provides novel insights into function and clinical impact of genes across the genome and clinical specialties
  Presenter: Claudia Langenberg
  Date/Time: October 16, 2025 | 2:30-4:30 p.m. | Poster Session 4105T | Proteogenomics

“It’s remarkable to see how rapidly proteomics is rising in importance among genomics researchers, as reflected in the many exciting presentations at ASHG,” said Omid Farokhzad, Chair and CEO of Seer. “Proteins are the functional drivers of biology, and the proteome is extraordinarily complex. Empowering researchers to connect genetic variation to biological function through deep, unbiased proteomics at scale will help unlock the next phase of precision medicine. We’re thrilled to see so many researchers choosing Seer’s platform to help them make these connections and discoveries.”

About Seer, Inc.

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.

For more information, please visit booth #2586 or contact us at pr@seer.bio.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Carrie Mendivil
investor@seer.bio

FAQ

When and where will Seer present at ASHG 2025 (SEER)?

Seer will present at ASHG 2025 in Boston during October 14-18, 2025 and will host a featured CoLab session on October 16, 2025 at 2:30-3:00 p.m. ET.

What topics will Seer cover in the CoLab session at ASHG 2025?

The CoLab session will cover multi-omic approaches using the Proteograph Product Suite, including xenotransplantation immune profiling and isoform-specific biomarkers in idiopathic pulmonary fibrosis.

Which presenters will speak in Seer’s ASHG 2025 session?

Presenters include Brendan Keating, PhD (NYU Langone Health) on gene-edited pig organ xenotransplants and Gloria Sheynkman, PhD (University of Virginia) on isoform-specific biomarkers in fibrosis.

What other Seer-related research will appear at ASHG 2025?

Independent groups will present Proteograph-based studies on October 16, including a poster on triangulating proteomic methods (Poster 4063T) and a proteogenomics poster session (Session 4105T).

How does Seer describe the role of proteomics relative to genomics?

Seer emphasizes that proteomics complements genomics by translating genetic variation into biological function and identifying protein-level biomarkers that advance precision medicine.

Which Seer product is featured in the ASHG presentations and what does it enable?

The presentations feature Seer’s Proteograph Product Suite, which is described as enabling deep, unbiased proteomic profiling and proteogenomic integration for biomarker discovery.